Alexion Pharmaceuticals (NASDAQ:ALXN) issued an update on its FY 2020
Pre-Market earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 10.65-10.95 for the period, compared to the Thomson Reuters consensus estimate of $10.88. The company issued revenue guidance of $5.55-5.6 billion, compared to the consensus revenue estimate of $5.41 billion.
Shares of Alexion Pharmaceuticals stock opened at $102.49 on Friday. The stock has a market cap of $22.63 billion, a P/E ratio of 27.40, a P/E/G ratio of 0.81 and a beta of 1.46. The company has a quick ratio of 3.82, a current ratio of 4.79 and a debt-to-equity ratio of 0.24. The business’s 50 day moving average is $110.49 and its 200-day moving average is $102.94. Alexion Pharmaceuticals has a 12-month low of $72.67 and a 12-month high of $125.52.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $3.11 EPS for the quarter, topping the consensus estimate of $2.32 by $0.79. The business had revenue of $1.44 billion during the quarter, compared to the consensus estimate of $1.27 billion. Alexion Pharmaceuticals had a net margin of 15.28% and a return on equity of 22.57%. On average, sell-side analysts expect that Alexion Pharmaceuticals will post 9.95 EPS for the current year.
A number of equities analysts have recently weighed in on ALXN shares. Credit Suisse Group increased their target price on Alexion Pharmaceuticals from $142.00 to $147.00 and gave the stock an outperform rating in a research note on Monday, June 1st. Zacks Investment Research cut Alexion Pharmaceuticals from a buy rating to a hold rating and set a $107.00 price objective on the stock. in a research report on Monday, May 18th. Cfra reduced their target price on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a strong-buy rating for the company in a research report on Wednesday, May 6th. ValuEngine lowered shares of Alexion Pharmaceuticals from a sell rating to a strong sell rating in a research report on Tuesday, July 28th. Finally, SunTrust Banks lifted their price objective on shares of Alexion Pharmaceuticals from $135.00 to $155.00 and gave the stock a buy rating in a research note on Friday. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $143.17.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Article: When can a hold rating present a buying opportunity?
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.